hiPSC-derived iMDSCs (Fate Therapeutics)

N/A

Report date: 2025/03/20 15:08:25

Base Information

Drug NamehiPSC-derived iMDSCs (Fate Therapeutics)
Drug Alias Namehuman induced pluripotent stem cell-derived myeloid derived suppressor cells (Fate Therapeutics)
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionImmunosuppressants
TargetsUpdating
Therapy Area/IndicationsInflammationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInflammationAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A